The Lyme Disease Association, Inc. (LDA) provides opinions on different topics about the medicine and the politics of tick-borne diseases (TBD) in this LDA Blog section of the website. This section is divided into the President’s Blog where the LDA President discusses timely issues on TBD and the LDA Guest Blogs from the perspective of knowledgeable individuals.
EXPECTATIONS: The recent Bloomberg article on the upcoming Lyme disease vaccine was not a surprise but was certainly a disappointment to the Lyme community and the Lyme Disease Association Inc. (LDA). The reporter spent time tracking me down to do an interview, as she indicated to me, many in the Lyme Community had suggested to her that I should be interviewed, probably due to the LDA’s involvement in the Lyme scene during the prior vaccine withdrawal.
LDA INVOLVEMENT IN EARLY VACCINE: At the time the first Lyme OspA vaccine, LymeRix®, was receiving FDA approval, with the most provisos− according to the chairperson−the LDA was already more than a decade into educating about and providing research funds for Lyme disease. As LDA president, I was educating in NJ and elsewhere. The prevailing questions and comments were always the same: talk and questions about the vaccine− problems that many people said they/acquaintances were experiencing and attributing to the vaccine.